A cell-based assay for the detection of neutralizing antibodies against alemtuzumab

Aim: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles. Results: Alemtuzumab–Alexa Fl...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Liaqat Ali, Gauri Saxena, Meleri Jones, Georgia R Leisegang, Luke Gammon, Sharmilee Gnanapavan, Gavin Giovannoni, Klaus Schmierer, David Baker, Angray S Kang
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Taylor & Francis Group 2020-04-01
סדרה:	BioTechniques
נושאים:	alemtuzumab antidrug antibodies multiple sclerosis neutralizing antibodies
גישה מקוונת:	https://www.future-science.com/doi/10.2144/btn-2019-0122
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!